Software (Web Marketplace Saas..) • BioTech • Businesses Solutions • Sales (& Marketing) • A.I. (& Big Data) • Web Security (& Privacy) • Developer tools • Online Social
Description
General Partner at CRV
Most Interested In
AI as applied to the real-world: autonomous vehicles, cyber security, demand forecasting, etc.
Also any SaaS application (B2B only)
Focused on Seed and A's only
Not Interested In
Not interested in Consumer software, FinTech, HC IT, Bio.
Not pursuing later stage deals
Software (Web Marketplace Saas..) • PropTech • IT (& TMT) • Hospitality (& Events) • Media • Education • BioTech • AgroTech • Businesses Solutions • FinTech (& Financials services) • Hardware (& Manufacturing) • Energy • Retail (& E-Commerce) • Sales (& Marketing) • Cosmetics (& Fashion) • Entertainment (& Sports) • IoT (& Wearables) • CleanTech • A.I. (& Big Data) • HealthTech (& Fitness) • Blockchain (& Cryptos) • Web Security (& Privacy) • Gaming (& eSports) • Advertising • Analytics • AR/VR • Cloud Services (& Infrastructure) • Developer tools • Future Of Work • Food & Beverage • Human Resources • Impact • Insurance (& InsurTech) • Payments • Robotics • Mobile Apps • Aerospace (& Defense) • Healthcare (& Wellness) • Music • Investment Management • LegalTech • Mobile • Mobility • Online Social • Consumer • Oil & Gas (& Mining) • Industrials • Film Production (& Distribution) • Semiconductors
Description
Jerry Yang serves as Founding Partner at AME Cloud Ventures. Yang also serves as Special Partner at Neotribe Ventures. He serves as Investor of BirdEye. He also serves as an Independent Director at Workday and Advisor at Radius. He is the Founding Partner at AME Cloud Ventures. He serves as Board Observer and Senior Advisor at Didi Kuaidi. Since March 2012, he has worked with and invests in technology entrepreneurs as the founding partner of AME Cloud Ventures, his innovation investment firm. He is also a co-founder of Yahoo! Inc., where he served as a director from March 1995 to January 2012, and as Chief Executive Officer from June 2007 to January 2009. He also led Yahoo!'s investments in Yahoo Japan and Alibaba Group Holding Limited, and he is a currently a director of Alibaba Group, where he has served on the board from October 2005 to January 2012 and from September 2014 to the present. He is also a director of Lenovo, Inc. where he has served on the board since November 2014. From July 2000 to November 2012, he was a member of Cisco Systems, Inc.'s Board of Directors, and he was a director of Yahoo! Japan from January 1996 to January 2012. He also is a director of various private companies and foundations. He received a B.S. and M.S. in Electrical Engineering from Stanford University, where he served as Vice Chair of the Board of Trustees from June 2005 until September 2016. He is also an Angel Investor. He serves as Board Member at Docker
Tony Corbin
Investing in BioTech • Businesses Solutions ...
Menlo Park , San Fran..., U.S.A. - Israel - Europe: Germany, United Kingdom, France, Italy, Spain, Poland, Romania, Netherlands, Belgium, Czech Republic, Greece, Portugal, Sweden, Hungary, Austria, Switzerland, Denmark, Finland, Slovakia, Norway, Ireland, Luxembourg, Malta, Icelan
Previous Investments
• Vayyar Imaging:
$109000000 (Later stage VC)
• VDOO:
$57000000 (Later stage VC)
• Cloudleaf:
$26000000 (Later stage VC)
• Fakespot:
(Series A)
• Fakespot:
$4000000 (Series A)
• Sumatra:
$2000000 (Seed)
• MRGN:
(Pre Seed)
• MRGN:
(Pre-Seed)
• Ash Wellness:
$3000000 (Seed)
• Ash Wellness:
(Seed+)
• AppliedXL:
$4000000 (Seed)
• AssetDash:
(Pre Seed)
• Tabula:
$3000000 (Pre Seed)
• Naya:
$6000000 (Seed)
• Thorium Data:
$100000 (Pre Seed)
• OpenAxis:
$2000000 (Pre Seed)
• CACTIVATE:
(Pre Seed)
• Grin Gaming:
(Seed)
• Grin Gaming:
(Seed)
• Docket:
(Seed)
• Ask Vera:
(Seed)
• UrsaLeo:
(Seed+)
• Cactivate:
(Pre-Seed)
• Clearforce:
(Seed)
• Paragon Intel:
(Seed+)
• Intrro:
(Seed)
• Bazze:
(Pre-Seed)
• Asset Dash:
(Pre-Seed)
• Extend:
$16000000 (Series A)
• OneCell Diagnostics:
$16000000 (Series A)
• Finicast:
$13000000 (Seed)
• Very Good Ventures:
$3000000 (Series A)
• Very Good Ventures:
$3000000 (Series A)
• Prellis Biologics:
$35000000 (Series C)
• Prellis Biologics:
$15000000 (Series B)
• Biomason:
$65000000 (Series C)
• Home Delivery Service (HDS Global):
$5000000 (Series Unknown)
• Rizzle:
$17000000 (Convertible Note)
• EnTribe:
$3000000 (Seed)
• Atonarp:
$50000000 (Series D)
• Atonarp:
$2000000 (Series B)
• Atonarp:
$4000000 (Series A)
• Boom Supersonic:
$50000000 (Series C)
• Extend, Inc.:
$16000000 (Series A)
• Quartic.ai:
$2000000 (Seed)
• Globality:
$27000000 (Series B)
• Globality:
$10000000 (Series A)
• BangDB:
(Seed)
• Reaction:
$10000000 (Series A)
• Reaction:
$2000000 (Seed)
• Shipster:
(Seed)
• H2O.ai:
$9000000 (Series A)
• Trove:
$5000000 (Series A)
• FUTR Corp.:
$5000000 (Seed)
• Yellowsmith:
$850000 (Seed)
• Printi:
$1000000 (Series A)
• GoPro:
$88000000 (Series A)
Tony Corbin
Menlo Park - San Francisco Bay Area - California, U.S.A. - Israel - Europe: Germany, United Kingdom, France, Italy, Spain, Poland, Romania, Netherlands, Belgium, Czech Republic, Greece, Portugal, Sweden, Hungary, Austria, Switzerland, Denmark, Finland, Slovakia, Norway, Ireland, Luxembourg, Malta, Icelan
Riverwood Capital is a globally-focused private equity firm that invests in high-growth businesses in the technology and services industries, across a variety of verticals and geographies. Riverwood has offices in Menlo Park, CA and New York, NY and currently has more than 20 investments in North America, Latin America and Asia. The firm's current fund has $780 million of committed capital. The final fund close was in April 2011. Riverwood invests in mid-market technology and technology enabled products and services. The firm defines mid-market as approximately $100-$500 million in revenue for product companies, and approximately $25-$150 million in revenue for software and services. Riverwood occasionally invests outside these ranges. Riverwood invests on a global basis, having already invested in the U.S., Israel, Argentina, Chile, and Brazil. The firm's normal investment size ranges from $25-75 million.
Cyril Bertrand is a Partner at Xange Captial where he is responsible for core-technology investments and for the German-speaking area.
Cyril has prior venture capital experience at DVC (Munich, Germany) where is was responsible for the Telecom & Semiconductor investments, and at TeleSoft Partners (San Mateo, CA).
Prior to that, his 7-year tenure at Alcatel brought him to the position of Director in charge of creating and growing Alcatel’s first generation of 802.11 products across France, Spain and Israel in 2000.
Cyril is also a non-exec board director of Apertio (UK), MergeOptics (Germany), Panoratio (Germany), Powerlase (UK) and is an observer at BigMachines (US).
Peter Levine serves as a General Partner at Andreessen Horowitz. He serves as the Board Member at Onshape, DigitalOcean and MakerLoop. Peter Levine serves as a General Partner at Andreessen Horowitz. Previously, he served as Senior Vice President of Citrix Systems. Levine is also a Board Member at GitHub, Cyanogen, Actifio, Tachyon Nexus, MixPanel and Instart Logic. Peter Levine is a general partner at Andreessen Horowitz. Peter was previously SVP and GM of the Data Center and Cloud Division at Citrix, where he was responsible for revenue, product management, business development and strategic direction. Peter joined Citrix in 2007 through its $500 million acquisition of XenSource, where he served as CEO. Prior to XenSource, Peter was a general partner at the Mayfield Fund. Before Mayfield, Peter was an early employee of VERITAS Software, where he helped to grow the organization to over 5,000 employees and more than $1.5 billion in revenue. Peter served as executive vice president and was responsible for marketing, OEM sales, business development and several product divisions. He is also currently a management lecturer at the Stanford Graduate School of Business and a former entrepreneurship lecturer at the Sloan School. He serves on the boards of Actifio, Bromium, Convergent.io, Mixpanel, Coho Data and Cynogen.
Erik Torenberg
Investing in Software (Web Marketplace Saas..) &b...
How to connect with Angel Investors in the BioTech industry?
In the BioTech industry, angel investors such as Esther Dyson, Vinod Khosla, and Steve Jurvetson are prominent figures. These investors focus on startups offering innovative solutions in biotechnology, genomics, and medical research. Esther Dyson, an entrepreneur and investor, looks for biotech startups that have the potential to make significant advancements in healthcare and medicine. Vinod Khosla, founder of Khosla Ventures, invests in high-impact biotech companies with disruptive technologies. Steve Jurvetson, a co-founder of Future Ventures, seeks out startups that push the boundaries of biological science and innovation. To connect with these investors, attend biotech conferences, medical expos, and networking events such as BIO International Convention, JP Morgan Healthcare Conference, and SynBioBeta. Utilize platforms like AngelList and LinkedIn to identify and reach out to potential investors. When pitching, emphasize how your biotech solution addresses key challenges in healthcare and medical research, such as developing new therapies, improving diagnostic accuracy, or advancing genomic research. Highlight any traction you’ve gained, such as partnerships with research institutions, successful clinical trials, or regulatory approvals. Building relationships through initial informal meetings or discussions at industry panels can help establish trust with these investors. Demonstrating the impact of your technology through case studies or clinical results can also add credibility. Personalize your outreach by referencing the investor’s previous investments and explaining how your venture aligns with their interests. Demonstrating a sustainable business model with clear revenue streams, such as licensing, product sales, or research grants, will further strengthen your pitch. Leveraging endorsements or case studies from biotech experts can also enhance your credibility.
Case Studies: Successful Funding Rounds with Angel Investors on Angels Partners
Exotic Orange & Angels Partners: Turning Financial Simplicity Into Investment Success
